Our mission

Antabio is a private biopharmaceutical company developing a broad pipeline of novel antibacterial treatments focused on drug-resistant life threatening infections. All Antabio programs address WHO critical priority pathogens and are eligible for streamlined development. Antabio has built a best in class, international team with highly successful track records including former executives from Novexel, Galapagos, Merck, GSK and Astra Zeneca. Antabio’s lead program MBLI (expected to enter the clinic in 2020) addresses a critical global threat that is already highly prevalent in Asia-Pacific. The company is targeting strategic partnerships in Asia-Pacific to maximize its peak sales potential. Antabio has raised over €18m in non-dilutive financing to date from Wellcome Trust (2 SDD awards, 2013 and 2015) and CARB-X (2017).  The company also completed a €12,5m series A round in 2017 with second closing in 2018.

Antabio has built an international team of experts to understand and resolve the most urgent unmet medical needs of the antibacterial space. We are dedicated to developing a pipeline of novel antibacterial treatments to address infections caused by WHO’s priority pathogens and fill important gaps in the antibiotic armamentarium

Marc Lemonnier – CEO, Antabio

HISTORY & KEY FACTS ABOUT ANTABIO

2013

Antabio’s metallo ß-lactamases inhibitor programme (MBLi) receives € 4.7 Million Award from the Wellcome Trust

Antabio receives a Wellcome Trust Seeding Drug Discovery  Award of €4.7m over 3 years to fund the development of a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases, from leads to preclinical candidate nomination. The project team was led by Principal Investigator Dr. Marc Lemonnier CEO of Antabio.

2015
antabio brainstormin

ANTABIO receives €4 Million to develop new drugs to treat chronic infections in Cystic Fibrosis patients.

This second Seeding Drug Discovery funding awarded to Antabio by the Wellcome Trust in as many years was used to support the discovery of a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the long-term management of chronic respiratory infections in CF patients.

2017

ANTABIO is awarded up to $8.9M from CARB-X to accelerate the development of its new treatment for chronic infections in Cystic Fibrosis patients

Antabio is awarded up to $8.9 million non-dilutive funding from CARB-X, the world’s largest public-private partnership devoted to antibacterial R&D. Antabio was selected by CARB-X from a group of 368 applicants worldwide and is part of the first cohort that includes companies from Continental Europe. The award provides funding to accelerate the development up to completion of Phase 1 clinical trials of Antabio’s PEI program (Pseudomonas Elastase Inhibitors) that seeks to develop a novel small molecule drug for the treatment of chronic Pseudomonas infections in Cystic Fibrosis patients.

ANTABIO raises € 7.3M Series A Financing to Develop Novel Treatments against Drug-Resistant Gram-negative infections

Antabio completes a €7.3M series A financing with subscriptions from investment funds iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion and from the company’s historical investors including former President of OM Pharma Christophe Ricard.

ANTABIO SUPPORT AND PARTNERS

Wellcome logo
Antabio bénéficie du soutien de l'union européenne et de la région occitanie
Galia, an investor in the antabio biopharmaceutical compagny
IRDI logo
IXO private equity logo
BNP Paribas développement
logo OMNES
Menu